


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zhongzhi Pharmaceutical Holdings Limited**

**中智藥業控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3737)**

### **CLARIFICATION ANNOUNCEMENT**

Reference is made to the announcement of Zhongzhi Pharmaceutical Holdings Limited published on 3 November 2022 (the “**Announcement**”). Terms used herein shall have the same meanings as defined in the Announcement unless the context requires otherwise. The Company wishes to make the following clarifications to the Announcement:

The headline of the Announcement shall be “CONTINUING CONNECTED TRANSACTION AND UPDATE IN CONTRACTUAL ARRANGEMENT” instead of “VOLUNTARY ANNOUNCEMENT”.

The announcement is made by Zhongzhi Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”). The purpose of this announcement is to keep the Shareholders and potential investors informed of the Continuing Connected Transaction and the latest business development of the Group.

By order of the Board  
**Zhongzhi Pharmaceutical Holdings Limited**  
**Mr. Lai Zhi Tian**  
*Chairman & Executive Director*

Hong Kong, 4 November 2022

*As at the date of this announcement, the Board comprises nine directors. The executive directors are Mr. Lai Zhi Tian, Mr. Lai Ying Feng, Mr. Lai Ying Sheng and Mr. Cao Xiao Jun. The non-executive directors are Ms. Jiang Li Xia and Mr. Peng Zhiyun. The independent non-executive directors are Mr. Ng Kwun Wan, Mr. Wong Kam Wah and Mr. Zhou Dai Han.*